Coya Therapeutics, Inc. Common Stock (COYA) - Net Assets
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has net assets worth $27.28 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.04 Million) and total liabilities ($4.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does Coya Therapeutics, Inc. Common Stock carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.28 Million |
| % of Total Assets | 85.15% |
| Annual Growth Rate | 47.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 147.68 |
Coya Therapeutics, Inc. Common Stock - Net Assets Trend (2020–2024)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore COYA current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Coya Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual net assets of Coya Therapeutics, Inc. Common Stock from 2020 to 2024. For live valuation and market cap data, see COYA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $39.58 Million | +11.06% |
| 2023-12-31 | $35.64 Million | +524.56% |
| 2022-12-31 | $-8.39 Million | -330.36% |
| 2021-12-31 | $3.64 Million | -56.11% |
| 2020-12-31 | $8.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Coya Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4000519100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.67K | 0.00% |
| Other Components | $80.31 Million | 202.93% |
| Total Equity | $39.58 Million | 100.00% |
Coya Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nusa Raya Cipta Tbk
JK:NRCA
|
$87.27 Million |
|
INLIF LIMITED Ordinary Shares
NASDAQ:INLF
|
$87.32 Million |
|
Apetit Oyj
HE:APETIT
|
$87.37 Million |
|
Elevate Uranium Ltd
AU:EL8
|
$87.37 Million |
|
Hasen-Immobilien AG
STU:ABHA
|
$87.20 Million |
|
Banco Santander Río S.A
BA:BRIO
|
$87.20 Million |
|
Sirtec International Co Ltd
TWO:5356
|
$87.16 Million |
|
FitLife Brands, Inc. Common Stock
NASDAQ:FTLF
|
$87.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Coya Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 35,635,609 to 39,577,095, a change of 3,941,486 (11.1%).
- Net loss of 14,880,787 reduced equity.
- New share issuances of 14,004,381 increased equity.
- Other comprehensive income increased equity by 11,249.
- Other factors increased equity by 4,806,643.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.88 Million | -37.6% |
| Share Issuances | $14.00 Million | +35.39% |
| Other Comprehensive Income | $11.25K | +0.03% |
| Other Changes | $4.81 Million | +12.15% |
| Total Change | $- | 11.06% |
Book Value vs Market Value Analysis
This analysis compares Coya Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.61x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.30x to 1.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $3.21 | $4.17 | x |
| 2021-12-31 | $0.55 | $4.17 | x |
| 2022-12-31 | $-0.84 | $4.17 | x |
| 2023-12-31 | $3.51 | $4.17 | x |
| 2024-12-31 | $2.60 | $4.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Coya Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -418.70%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.12x
- Recent ROE (-37.60%) is above the historical average (-41.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -13.25% | 0.00% | 0.00x | 1.05x | $-1.93 Million |
| 2021 | -134.25% | 0.00% | 0.00x | 1.32x | $-5.26 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.41 Million |
| 2023 | -22.42% | -133.08% | 0.15x | 1.16x | $-11.55 Million |
| 2024 | -37.60% | -418.70% | 0.08x | 1.12x | $-18.84 Million |
Industry Comparison
This section compares Coya Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Coya Therapeutics, Inc. Common Stock (COYA) | $27.28 Million | -13.25% | 0.17x | $87.25 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration int… Read more